\R\R\Nronald L. Rabin

\R\Nronald L. Rabin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


\R\Nronald L. Rabin has a total of 154 co-authors. Here are the top co-authors by number of shared publications:

  • Philippa Hillyer

    Laboratory of Immunobiochemistry, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States

    8 shared publications
  • Lynnsie M. Schramm

    Laboratory of Immunobiochemistry, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States

    5 shared publications
  • Aaron Chen

    Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (US-FDA), Silver Spring, MD, United States

    4 shared publications
  • Hilary Novatt

    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA

    4 shared publications
  • Daniela Verthelyi

    Center for Drug Evaluation and Research, US Food and Drug Administration

    3 shared publications
  • Debasis Panda

    Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States

    3 shared publications

Latest Publications

  • Open Access

    Biomarker-driven drug development for allergic diseases and asthma: An FDA public workshop

    by Ronald L. Rabin, Matthew C. Altman, S. Hasan Arshad, Richard D. Beger, Pamela A. Frischmeyer-Guerrerio, Elena Goleva, Robert G. Hamilton, Gurjit K. Khurana Hershey, Mohamed H. Shamji, Hugh A. Sampson, et al.


  • Open Access

    The Potential of Human Monoclonal IgE Antibodies to Establish Biological Potency and Stability of Allergen Extracts

    by Ronald L. Rabin

    Purpose of Review: Allergenic extracts are often standardized to control for potency, either by measuring concentrations of major allergens or “overall allergenicity” by competition for IgE in pooled sera from highly allergic subjects with a reference extract. Recent developments present an opportunity to use human mAb cloned from highly allergic subjects to define potency of allergenic extracts. Recent Findings: Two recent developments present an opportunity for revising potency measurements of allergen extracts: cloning allergen specific IgE from allergic subjects and extensive epitope mapping of major allergenic proteins. Summary: Because human IgE mAb recognize biologically relevant epitopes, they present a novel opportunity to determine the potencies of allergenic extracts and may contribute to the science base for allergen standardization.


  • Open Access

    A human monoclonal antibody based immunoenzymetric assay to measure Fel d 1 concentrations in cat hair and pelt allergenic extracts

    by \R\Nronald L. Rabin, Derek Croote, Aaron Chen, Ekaterina Dobrovolskaia, Joyce Jia Wen Wong, Jessica Grossman, Robert G. Hamilton\R\N

    In the United States, 19 allergen extracts of different specificities are standardized, which means that their potencies are determined in comparison to a US reference standard. For cat allergen extracts, potency is determined by measuring Fel d 1 content expressed in in Fel d 1 units, and with a unitage that correlates with skin test reactions (bioequivalent allergy units or BAU). Currently, Fel d 1 content is measured with a radial immunodiffusion (RID) assay that uses polyclonal sheep antisera to detect the allergenic protein by producing a white precipitin line in agar gel. However, the RID is considered cumbersome, and the polyclonal sera may qualitatively vary among animals and may recognize epitopes irrelevant to human allergic disease. In this report, we describe a quantitative two-site immunoenzymetric assay (IEMA) for Fel d 1 that uses immobilized capture and soluble biotin-labeled detection Fel d 1-specific human IgE monoclonal antibodies (mAb) that have been class-switched to IgG4. Together, they sandwich Fel d 1 molecules from extracts. Using purified natural Fel d 1 as a calibrator, the historically reported ∼4 micrograms Fel d 1/Fel d 1 unit assignment was directly measured in this mAb-based IEMA at 3.12 ± 0.24 micrograms of Fel d 1 per Fel d 1 unit. This IEMA appears to be equivalent to RID in the measurement of biological potencies of commercial cat hair and cat pelt extracts marketed in the United States.


  • Open Access

    Shared and Unique Features of Human Interferon-Beta and Interferon-Alpha Subtypes

    by Megen C. Wittling, Shannon R. Cahalan, Eric A. Levenson, Ronald L. Rabin

    Type I interferons (IFN-I) were first discovered as an antiviral factor by Isaacs and Lindenmann in 1957, but they are now known to also modulate innate and adaptive immunity and suppress proliferation of cancer cells. While much has been revealed about IFN-I, it remains a mystery as to why there are 16 different IFN-I gene products, including IFNβ, IFNω, and 12 subtypes of IFNα. Here, we discuss shared and unique aspects of these IFN-I in the context of their evolution, expression patterns, and signaling through their shared heterodimeric receptor. We propose that rather than investigating responses to individual IFN-I, these contexts can serve as an alternative approach toward investigating roles for IFNα subtypes. Finally, we review uses of IFNα and IFNβ as therapeutic agents to suppress chronic viral infections or to treat multiple sclerosis.


  • Oral Immunotherapy for Food Allergy—a US Regulatory Perspective

    by Kathleen Hise, Ronald L. Rabin

    The recent approval of Palforzia for treatment of peanut allergy by the US Food and Drug Administration (USFDA) predicts that additional products for oral immunotherapy (OIT) are on the horizon. In this article, the authors review the legal framework by which the USFDA regulates products for OIT of food allergy and the clinical data that demonstrated that the safety and effectiveness profile of Palforzia supported approval and conclude with a discussion of oral food challenge (OFC) as a clinical endpoint to demonstrate safety and effectiveness of OIT products.


  • Open Access

    Lack of Activation Marker Induction and Chemokine Receptor Switch in Human Neonatal Myeloid Dendritic Cells in Response to Human Respiratory Syncytial Virus

    by Cyril Le Nouën, Philippa Hillyer, Eric Levenson, Craig Martens, Ronald L Rabin, Peter L Collins, Ursula J Buchholz

    Respiratory syncytial virus (RSV) causes disease early in life and can reinfect symptomatically throughout life without undergoing significant antigenic change. In contrast, reinfection by influenza A virus (IAV) requires antigenic change. The adaptive immune response depends on antigen presentation by dendritic cells (DC). We used myeloid DC (mDC) from cord blood and adult blood donors to evaluate whether immunological immaturity contributes to the inability to mount a fully protective immune response to RSV. While IAV induced some activation and chemokine receptor switching in cord blood mDC, RSV did not. This appeared to be due to a lack of activation and a weak and mostly reversible inhibition of DC functions. Both viruses induced a stronger activation of mDC from adults than mDC from cord blood. Thus, inefficient stimulation of mDC by RSV and immunological immaturity may contribute to reduced immune responses and increased susceptibility to RSV disease and reinfection in young infants.


  • Open Access

    IRF1 Maintains Optimal Constitutive Expression of Antiviral Genes and Regulates the Early Antiviral Response

    by Debasis Panda, Erisa Gjinaj, Mahesh Bachu, Erica Squire, Hilary Novatt, Keiko Ozato, Ronald L. Rabin

    Viral defense at mucosal sites depends on interferons (IFN) and IFN stimulated genes (ISGs), either of which may be constitutively expressed to maintain an “antiviral state” (AVS). However, the mechanisms that govern the AVS are poorly defined. Using a BEAS-2B respiratory epithelial cell line deficient in IRF1, we demonstrate higher susceptibility to infection with vesicular stomatitis virus (VSV) and influenza virus. IRF1-mediated restriction of VSV is IFN-independent, as blockade of types I and III IFNs and JAK-STAT signaling before infection did not affect VSV infection of either parent or IRF1 KO cells. Transcriptome analysis revealed that IRF1 regulates constitutive expression of ~300 genes, including antiviral ISGs: OAS2, BST2, and RNASEL and knockdown of any of these IRF1-dependent genes increased VSV infection. Additionally, IRF1 enhances rapid expression of IFNβ and IFNλ after stimulation with poly I:C and also regulates ISG expression. Mechanistically, IRF1 enhances recruitment of BRD4 to promotor-enhancer regions of ISGs for rapid expression and maintains levels of histone H3K4me1 for optimal constitutive expression. Finally, IRF1 also regulates constitutive expression of TLR2 and TLR3 and promotes signaling through these pattern recognition receptors (PRR). These data reveal multiple roles for IRF1 toward effective anti-viral responses by maintaining IFN-independent constitutive expression of anti-viral ISGs and supporting early IFN-dependent responses to PRR stimulation.


  • S27 of IFNα1 Contributes to Its Low Affinity for IFNAR2 and Weak Antiviral Activity

    by Nikunj Sharma, Anya J. O'NEal, Christian Gonzalez, Megen Wittling, Erisa Gjinaj, Lisa M. Parsons, Debasis Panda, Alexey Khalenkov, Dorothy Scott, Saurav Misra, et al.

    Type I interferons (IFNs) signal by forming a high affinity IFN-IFNAR2 dimer, which subsequently recruits IFNAR1 to form a ternary complex that initiates JAK/STAT signaling. Among the 12 IFNα subtypes, IFNα1 has a uniquely low affinity for IFNAR2 (in vitro. Structural modeling suggests that S27 of IFNα1 disrupts the IFNα:IFNAR2 hydrophobic interface that is otherwise stabilized by F27 and that replacing S27 with phenylalanine partially restores the hydrophobic surface. Disruption of the hydrophobic IFNα:IFNAR2 interface by the unique S27 of IFN α1 contributes to its low affinity and weak antiviral activity.


  • Strand-Specific Dual RNA Sequencing of Bronchial Epithelial Cells Infected with Influenza A/H3N2 Viruses Reveals Splicing of Gene Segment 6 and Novel Host-Virus Interactions

    by Giulia Fabozzi, Andrew J. Oler, Poching Liu, Yong Chen, Samuel Mindaye, Michael A. Dolan, Heather Kenney, Marjan Gucek, Jun Zhu, Ronald L. Rabin, et al.

    The use of massively parallel RNA sequencing (RNA-seq) has revealed insights into human and pathogen genomes and their evolution. Dual RNA-seq allows simultaneous dissection of host and pathogen genomes and strand-specific RNA-seq provides information about the polarity of the RNA. This is important in the case of negative-strand RNA viruses like influenza virus, which generate positive (complementary and mRNA) and negative-strand RNAs (genome) that differ in their potential to trigger innate immunity. Here, we characterize interactions between human bronchial epithelial cells and three influenza A/H3N2 strains using strand-specific dual RNA-seq. We focused on this subtype because of its epidemiological importance in causing significant morbidity and mortality during influenza epidemics. We report novel elements that differ between seasonal and laboratory strains highlighting the complexity of the host-virus interplay at the RNA level.